English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Somatostatin analogs (SSAs) are antisecretory agents that have been used to control hormonal syndromes associated with neuroendocrine tumors for more than 20 years. Recent phase III randomized, placebo controlled trials demonstrated their antiproliferative effects. The PROMID study showed that octreotide LAR (long-acting repeatable) treatment had anti-tumor effects. CLARINET, an international multicenter controlled study, provides new evidence that lanreotide has antiproliferative effects. Depot lanreotide significantly prolonged progression-free survival among patients with metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Because GEP-NETs are biologically diverse in terms of primary tumor site and functional status, preventing progression can be difficult.

Antiproliferative Effect of Somatostatin Analogs – Data Analyses and Clinical Applications in the Context of the CLARINET Study